Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Targeted-Synthetic DMARDs
The role of bDMARDs and tsDMARDs in the treatment of rheumatological conditions continues to evolve and is an area that has significant implications for all practitioners and patients. This edition has been developed to support practitioners in the safe and effective assessment, screening and management of patients when these drugs are being considered.
It provides a best practice framework for rheumatology specialist practitioners and the wider health care team involved in supporting the administration, monitoring and delivery of care to patients in a variety of settings.
Some of our publications are also available in hard copy, but this may entail a small charge. For more information and to order a hard copy please call 0345 772 6100 and select option five. The line is open Monday-Friday (excluding bank holidays) between 10am-4pm.
You can download all electronic publications from the RCN free of charge.
Published by the ÃÛÌÒÖ±²¥, 20 Cavendish Square, London, W1G 0RN.
© 2016 ÃÛÌÒÖ±²¥. This publication in hard copy format may not be lent, resold, hired out or otherwise disposed of by way of trade in any form of binding or cover other than that in which it is published, without the prior consent of the publishers.
For permission to reproduce RCN copyrighted text, please complete our copyright request form.
Page last updated - 13/08/2024